

## **PROGRAM:**

3rd IAEA RER6039 Regional Workshop on Hadron Therapy

Hadron Therapy Workshop: status and perspectives, plans for next generation facilities

Date: 18 and 19 October 2024

Venue: Concert Hall, Thessaloniki, Greece

web page: <a href="https://indico.cern.ch/e/HadronTherapyWorkshop">https://indico.cern.ch/e/HadronTherapyWorkshop</a>

(Times indicated are CEST i.e. UTC+2)

# Friday 18th October 2024

#### SESSION 1 - HADRON THERAPY OVERVIEW

**Moderators: Manjit Dosanjh** 

<u>Time</u>	<u>Tittle</u>
08:30 - 08:45	Participants registration
08:45 - 09:15	Welcome Addresses  Maria Bigaki (IAEA CP, Papageorgiou), Sotirios Charisopoulos (IAEA), Sandro Rossi (HITRIplus, CNAO), Panagiotis Bamidis (AUTH, AHEPA)
09:15 - 09:35	Historic and scientific evolution of Hadron Therapy  Ugo Amaldi (TERA) and Sandro Rossi (CNAO)
09:35 - 09:55	Hadron Therapy in clinical practice  Ester Orlandi (CNAO, Uni Pavia)
09:55 – 10:15	Radiobiology of Hadron Therapy  Angelica Facoetti (CNAO)
10:15 – 10:35	HITRIplus project, its impact on boosting research in South East Europe and future perspectives  Sanja Damjanovic (GSI)









































Socio-economic benefits of accelerator based Hadron Therapy facilities 10:35 - 10:55

**Sotirios Charichopoulos (IAEA)** 

10:55 - 11:30 Coffee Break

## SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

### **Moderators: Roberto Orecchia**

<u>Time</u>	<u>Tittle</u>
11:30 - 11:50	Hadron Therapy : from pioneering times towards the future
	Manjit Dosanjh (Uni Oxford)
11:50 - 12:10	SEEIIST facility design and alternatives
	Maurizio Vretenar (CERN)
12:10 - 12:30	CERN as an example of large scale infrastructure
	Emmanuel Tsesmelis (CERN)
12:30 – 12:50	Status and vision of the SEEIIST project
	Leandar Litov (Uni Sofia)
12:50 – 13:30	Round table – SEEIIST towards to the Future
	Introduction: cancer incidence in SEE, Mimoza Ristova (Uni Skopje)
13:30 - 13:45	Concluding remarks
	Roberto Orecchia
13:45 – 15:00	Lunch Break











































## SESSION 3 – EXPERIENCES OF MULTIPARTICLE THERAPY FACILITIES IN OPERATION IN EUROPE

## **Moderators:**

<u>Time</u>	<u>Tittle</u>
15:00 - 15:20	Hadron Therapy at GSI - where we come from, where we go
	Konrad Lehmann (GSI)
15:20 - 15:40	The HIT facility, technology, clinical applications and research: novel approaches in particle therapy  Andrea Mairani (HIT)
15:40 - 16:00	The Marburg facility
	Klemens Zink (MIT)
16:00 – 16:20	The Krakow Hadron Therapy facility, lessons learnt
	Pawel Olko (IFJPAN)
16:20 – 16:40	Role of imaging
	George Dedes (LMU)
16:40 – 17:00	Coffee Break

















































## SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

**Moderators: Laura Vallow** 

<u>Time</u>	<u>Tittle</u>
17:00 - 17:20	Accelerator developments for medical and societal applications
	Yiannis Papaphilippou (CERN)
17:20 - 17:35	Optimisation for pre-injectors for hadron therapy
	Aris Mamaras (CERN/AUTH)
17:35 – 17:50	Optimisation of double use linac injector for hadron therapy facilities
	TBC
17:50 – 18:05	An ion source project as a seed to boost development of accelerator technologies in Bosnia-
	and-Herzegovina
	TBC
18:05 – 18:20	Development of the first table-top X-ray FLASH system
	Elpida Theodoridou (DKFZ, Uni Malta), Joao Seco (DKFZ, Uni Heidelberg)
18:20 – 18:30	Concluding remarks
	Laura Vallow
20:30	Welcome addresses by political and other authorities
	Concert and Welcome Drink









































# Saturday 19th October 2024

# Session 5 – INDICATIONS FOR HADRON THERAPY

**Moderators: Arnold Pompos, Joao Seco** 

<u>Time</u>	<u>Tittle</u>
09:00 - 09:20	Indications and clinical applications of HT at the Marburg facility  Fabian Eberle (MIT)
09:20 – 09:40	Chordoma treatments at CNAO  Maria Rosaria Fiore (CNAO)
09:40 – 10:00	Sarcoma treatments in Greece TBC
10:00 – 10:20	Modern radiation therapy techniques for head-and-neck cancer  Petros Alexidis (PAPAGEORGIOU)
10:20 – 10:40	Proton versus photon radiation therapy: advantages and disadvantages  Efstathios Kamperis (PAPAGEORGIOU)
10:40 – 11:00	Personalization of Hadron Therapy for H&N cancers: Patient Triage Based upon Bioindicators of Radioresistance  Michael D. Story (Mayo Clinic)
11:00 – 11:05	Concluding remarks Arnold Pompos, Joao Seco
11:05 – 11:30	Coffee Break















































## SESSION 6 - SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

**Moderators: Sandro Rossi** 

<u>Time</u>	<u>Tittle</u>
11:30 - 11:50	Tools to support the EU networking on hadron therapy
	Lisa Licitra (CNAO, Uni Milan)
11:50 - 12:10	Hadron therapy cost-benefit analysis applied to operations in CNAO
	Maria Vittoria Livraga (CNAO)
12:10 - 12:30	Caring for cancer patients: the CNAO social approach
	Silvia Meneghello (CNAO)
12:30 – 12:45	Citizen and Patient Science
	Stefania Oikonomou (Web2Learn)
12:45 – 13:00	Empowering patient advocacy and cancer prevention
	Panagiotis Bamidis (AUTH/AHEPA, ELEVIT))
	The role of biomedical and clinical engineering societies in advancing and promoting Hadron Therapy on a national and international level
	Alkinoos Athanasiou (AUTH, ELEVIT)
13:10 – 13:30	Hadron Therapy in Greece
	EOPPY Delegate TBC
13:30 – 13:35	Concluding remarks
	Sandro Rossi
13:35 – 15:00	Lunch Break















































## SESSION 7 - PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

Moderators: Antonio Capizzello, Emmanouel Chatzipantelis, Papakonstantinou Eugenia, Semi Harrabi

<u>Time</u>	<u>Tittle</u>
15:00 - 15:20	Hadron therapy state-of-the art in pediatric oncology-clinical aspects
	Sabina Vennarini (CNAO)
15:20 - 15:40	Treatment planning for pediatric cancer tumour treatments
	Silvia Molinelli (CNAO)
15:40 - 16:00	Pediatric patients referred for hadron therapy
	Barbara Rombi (TRENTO)
16:00 -16:20	Pediatric patients commonly referred for Radiotherapy
	Capizzello Antonio (AUTH / AHEPA)
16:20 – 16:50	Coffee Break
16:50 - 18:20	Panel discussion: Paediatric Oncology in Greece
	Emmanouel Chatzipantelis (AHEPA), Eugenia Papakonstantinou (IPPOKRATEION)
	Nikos Foroglou (AHEPA), Christos Stefanidis (IPPOKRATEION), George Giakoumetis (AHEPA)
18:20 – 18:30	Concluding remarks
	Semi Harrabi















































## SPEAKERS FUNCTIONS AND AFFILIATIONS

Speakers biographies, functions and affiliations can be found here.

#### SESSION 1 - HADRON THERAPY OVERVIEW

### **Ugo Amaldi**

Founder and president of the TERA foundation, Novara, Italy

#### Sandro Rossi

Director General, National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy

### Maria Bigaki

Program Office Manager at Papageorgiou General Hospital, Thessaloniki, Greece

### **Ester Orlandi**

Chief of Clinical Department, National Center for Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy

### **Angelica Facoetti**

Head of experimental Radiobiology activities at CNAO, Pavia, Italy

### Sanja Damjanovic

Senior Researcher, EU-office, GSI, Germany

## **Sotirios Charichopoulos**

IAEA Technical coordinator of Regional Project Cooperation project RER6038 that supports capacity building in South East Europe

### SESSION 2 – HADRON THERAPY DEVELOPMENTS AND FUTURE PERSPECTIVES

#### **Manjit Dosanjh**

Former Senior Advisor for Medical Applications at CERN, Geneva, Switzerland. Visiting Professor at University of Oxford (U.K.). She has coordinated the ENLIGHT (European Network for Light Ion Hadron Therapy) Network since 2006. She is the Networking Pillar for the HITRIplus project. Project Leader for STELLA (Smart Technologies to Extend Lives with Linear Accelerators)











































#### **Maurizio Vretenar**

Group leader of CERN NIMMS Next Ion Medical Machine Study

#### **Emmanuel Tsesmelis**

CERN International Relations, Prof Uni Oxford

#### **Leandar Litov**

Associate Professor in Particle Physics. Head, Atomic Physics Department · Faculty of Physics, Uni of Sofia

## **Roberto Orecchia**

Scientific Director and Head of the Department of Medical Imaging and Radiation Sciences, European Institute of Oncology-IEO IRCCS, Milan, Italy

### SESSION 3 – EXPERIENCES OF MULTIPARTICLE THERAPY FACILITIES IN OPERATION IN EUROPE

### **Konrad Lehmann**

Senior Researcher, Biophysics Department, GSI, Germany

#### **Andrea Mairani**

Prof. Dr. Group Leader, Medical Physicist at Heidelberg Ion Beam Therapy Center, Germany

### Klemens Zink

Technical director, Marburg Ion Therapy Centre, Germany

## **Pawel Olko**

Head of Division of Applications of Physics, Institute of Nuclear Physics Polish Academy of Sceinces (IFJ PNA)

## **George Dedes**

Scientific Staff Member, Senior Lecturer, LMU, Munich, Germany

## SESSION 4 – ADVANCES IN ACCELERATOR TECHNOLOGIES FOR HADRON THERAPY FACILITIES

# **Yiannis Papaphilippou**

Group Leader of CERN Accelerators and Beam Physics group

## **Aris Mamaras**

PhD Student at CERN and AUTH, Thessaloniki, Greece














































#### **Lazar Nikitovic TBC**

PhD, Researcher at CERN, Technical Uni Riga, Uni Montenegro

## **Amar Ajanovic TBC**

PhD, Researcher at CERN, Group Leader at UNSA, Sarajevo, BiH

## Elpida Theodoridou

MSc Student at DKFZ and Uni Malta

### **Laura Vallow**

Department chair, Professor of Radiation Oncology, Mayo Clinic Florida, US

### **SESSION 5 – INDICATIONS FOR HADRON THERAPY**

#### **Fabian Eberle**

Priv.-Doz. Dr. med. Senior physician, ion beam therapy, Marburg Ion Therapy Center, Germany

#### **Maria Rosaria Fiore**

Radiation Oncologist (Chordoma and Chondrosarcoma - Sacrum and Spine), CNAO, Pavia, Italy

### **Yiannis Boukovinas TBC**

Medical Oncologist, Head of Oncologic Unit at Bioclinic, Thessaloniki, Greece

### **Petros Alexidis**

Radiation oncologist at Interbalkan European Medical Center, Papageorgiou General Hospital and AUTH, Thessaloniki, Greece

## **Efstathios Kamperis**

Radiation oncology consultant at Papageorgiou General Hospital, Thessaloniki, Greece

## Michael D. Story

Prof, Consultant, Mayo Clinic, Florida, USA

## Joao Seco

Professor and Division Head, BioMedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ) and University of Heidelberg, Germany













































### **Arnold Pompos**

Professor of Physics, Associate Vice Chair for Strategic Initiatives and Capital Investments, The University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, USA

### SESSION 6 - SOCIO-ECONOMIC ASPECTS RELATED TO HADRON THERAPY

### Lisa Licitra

Director SC of Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Associated Professor at Università degli Studi di Milano, Italy. Scientific Director of the Italian National Center for Oncological Hadrontherapy, CNAO, Pavia Italy

## Maria Vittoria Livraga

Head of Finance and Administration at CNAO, Pavia, Italy

### Silvia Meneghello

Head of Communications, CNAO, Pavia, Italy

#### Stefania Oikonomou

Political Scientist, digital learning and social participation expert at Web2Learn

## **Panagiotis Bamidis**

Professor, Medical Physics, Informatics and Medical Education, Aristotle University of Thessaloniki School of Medicine President, Hellenic Society of Biomedical Technology (ELEVIT)

## **Alkinoos Athanasiou**

Assistant Professor of Neurosurgery, Aristotle University of Thessaloniki (AUTH) *Vice-President, Hellenic Society of Biomedical Technology (ELEVIT)* 

## SESSION 7 - PEDIATRIC ONCOLOGY AND ROLE OF HADRON THERAPY

## Sabina Vennarini

Head of Pediatric Radiation Unit in INT Fondazione IRCCS Istituto Nazionale Tumori and Senior Clinical Consultant for Pediatric Proton Therapy CNAO, Pavia, Italy

### Silvia Molinelli

Medical physicist responsible for treatment planning and carbon ion modelling, CNAO, Pavia, Italy

### Semi Harrabi















































Radiation oncologist (Oberarzt), University Hospital Heidelberg, Primary responsible for Heidelberg Ion Beam Therapy Centre

#### **Barbara Rombi**

Radiation Oncologist Proton Therapy Center Trento Italy

## **Antonio Capizzello**

Ass. Professor of Aristotle University of Thessaloniki, Radiotherapy oncology department, AHEPA University Hospital, Thessaloniki Greece

### **Emmanouel Hatzipantelis**

Professor of Aristotle University of Thessaloniki, Thessaloniki Greece

Professor of Paediatrics - Pediatric Hematology, Oncology, 2nd Department of Pediatrics, University Hospital AHEPA, Thessaloniki Greece

## **Nicolas Foroglou**

MD, PhD, Professor Aristotle University of Thessaloniki,

Professor of Neurosurgery at the Department of Neurosurgery, AHEPA University Hospital, Thessaloniki Greece

## **Evgenia Papakonstantinou**

MD MSc PhD Head of pediatric Oncology Department at Hippokration General Hospital, Thessaloniki Greece

### **Christos Stefanidis**

Pediatric Oncology Surgery Department at Hippokration General Hospital, Thessaloniki Greece

### **George Giakoumetis**

Medical Physics Department, AHEPA University Hospital, Thessaloniki Greece











































